Related Experiment Video

Updated: Jun 14, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Lytic peptide-mediated sensitization of TRAIL-resistant prostate cancer cells to death receptor agonists

Sutapa Barua1, Rebecca S Linton, Jennifer Gamboa

  • 1Chemical Engineering, Arizona State University, Tempe, AZ 85287-6106, United States.

Cancer Letters
|March 30, 2010
PubMed

Insights

Lytic peptides like KLA can sensitize TRAIL-resistant prostate cancer cells to death receptor (DR) agonists. This combination therapy enhances cancer cell death through apoptosis, offering a novel approach for advanced cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tumor Necrosis Factor-alpha Related Apoptosis Inducing Ligand (TRAIL) and death receptor (DR) agonists show promise in cancer therapy by selectively inducing apoptosis in cancer cells.
  • However, resistance to TRAIL-mediated apoptosis is a significant challenge in treating various cancers, including prostate cancer.

Purpose of the Study:

  • To investigate the potential of a cationic amphipathic lytic peptide, KLA, in chemosensitizing TRAIL-resistant human prostate cancer cells (LNCaP and PC3-PSMA) to DR agonistic antibodies.
  • To explore the synergistic effects and underlying mechanisms of combining KLA with DR agonists for cancer cell ablation.

Main Methods:

  • Treatment of TRAIL-resistant prostate cancer cell lines with KLA alone, DR agonists alone, and a combination of KLA followed by DR agonists.
  • Assessment of cell viability and apoptosis induction.
  • Measurement of activated caspase-3 cleavage and cytochrome-C protein levels.
  • Analysis of DR5 and lipid raft localization in cells.

Main Results:

  • Single-agent treatment with DR agonists did not significantly reduce the viability of resistant prostate cancer cells.
  • Combination treatment with KLA followed by DR agonists resulted in significantly greater cancer cell death compared to individual treatments, indicating synergy.
  • The combination therapy led to increased levels of activated caspase-3 and cytochrome-C, confirming the activation of the caspase-mediated apoptotic pathway.
  • KLA treatment enhanced the localization of DR5 and lipid rafts in LNCaP cells.

Conclusions:

  • Lytic peptides, such as KLA, can effectively sensitize TRAIL-resistant prostate cancer cells to DR-mediated apoptosis.
  • The combination of lytic peptides and DR agonists represents a novel and synergistic therapeutic strategy for the ablation of advanced cancer cells.
  • This approach warrants further investigation for developing new combination treatments in oncology.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Concept Videos

The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...